ANIK (Anika Therapeutics) NonCurrent Deferred Liabilities: $0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ANIK Anika Therapeutics Inc ANIK
66 GF Score
Price $19.28
GF Value $19.03
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Anika Therapeutics NonCurrent Deferred Liabilities?

Anika Therapeutics ANIK +6.70% 66 NonCurrent Deferred Liabilities is $0.0 Mil as of Jun. 2026. GuruFocus rates ANIK with a GF Score™ of 66/100 and a GF Value™ of $19.03 (Fairly Valued). The stock has 4 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Anika Therapeutics's non-current deferred liabilities for the quarter that ended in Jun. 2026 was $0.0 Mil.

Anika Therapeutics NonCurrent Deferred Liabilities Related Terms

Anika Therapeutics NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Anika Therapeutics's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anika Therapeutics NonCurrent Deferred Liabilities Chart

Anika Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.16 6.44 0.00 0.00 0.00

Anika Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ANIK
66GF Score
Anika Therapeutics Inc ANIK
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of $0.0 Mil mean?
Anika Therapeutics (ANIK) has a NonCurrent Deferred Liabilities of $0.0 Mil as of Jun. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Anika Therapeutics and its competitors.
Is Anika Therapeutics' NonCurrent Deferred Liabilities too high?
Anika Therapeutics' current NonCurrent Deferred Liabilities is $0.0 Mil. Overall, Anika Therapeutics has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Anika Therapeutics' NonCurrent Deferred Liabilities compare to SIGA and DERM?
Anika Therapeutics' NonCurrent Deferred Liabilities of $0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Drug Manufacturers company?
A good NonCurrent Deferred Liabilities depends on the Drug Manufacturers industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Anika Therapeutics and its competitors. Anika Therapeutics's current NonCurrent Deferred Liabilities is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anika Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Anika Therapeutics (ANIK) is currently considered Fairly Valued. The stock's GF Value™ is $19.03, compared to a current price of $19.28 — trading 1.3% above its estimated fair value. The current NonCurrent Deferred Liabilities is $0.0 Mil. Anika Therapeutics' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Anika Therapeutics (ANIK), the current NonCurrent Deferred Liabilities is $0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Anika Therapeutics (ANIK) Overvalued in 2026?

Based on GuruFocus' analysis, Anika Therapeutics stock appears to be overvalued. The current stock price of $19.28 is trading 1.3% above its estimated GF Value™ of $19.03. GuruFocus considers Anika Therapeutics to be Fairly Valued.

Key valuation signals for ANIK:

  • NonCurrent Deferred Liabilities: $0.0 Mil
  • GF Value™: $19.03 vs. price of $19.28 (1.3% above fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the ANIK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Anika Therapeutics Business Description

Other Exchanges AKP:Germany
Address 32 Wiggins Avenue, Bedford, MA, USA, 01730
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
66GF Score

Get the complete analysis for ANIK

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.28
Price
$19.03
GF Value